Isis Pharmaceuticals (ISIS) 52.64 $ISIS
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - 19 mins ago
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.35 (unch), KNMD: (), VTAE: 9.81 (-0.09), LLY: 85.01 (-0.67), OMER: 16.10 (-0.26), JNJ: 99.95 (+0.93), ISIS: 52.64 (-1.76), OPK: 16.67 (-0.17), GILD: 116.67 (+3.60), AZN: 32.83 (+0.02), MRK: 58.73 (+1.21), CCXI: 8.52 (-0.10), VBLT: 6.13 (-0.02), NVS: 103.80 (+1.01)
Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles
M2 - Tue Jul 28, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vhmx/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - BioDiem Ltd - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - R-Tech Ueno, Ltd. - ReNeuron Group Plc - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AMRS-001 - Antibodies to Antagonize IL-6 for Retinitis - BDM-E - BNP-RP - CB-11 - ECL-1 - emixustat hydrochloride - FIB-111 - Gene Therapy for Glaucoma and Retinitis Pigmentosa - Gene Therapy for Ocular Diseases - Gene Therapy for Ophthalmology - Gene Therapy for Retinitis Pigmentosa - Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - GS-020 - GT-038 - ISISRHO-2.5Rx - KIRA-6 - NT-501 - OCU-100 - PRO-015 - proinsulin human SR - QLT-091001 - Recombinant Human Nerve Growth Factor - ReN-003 - Retinal Progenitor Cells for Ophthalmological Disorders - RGX-321 - RST-001 - SAR-421869 - SHP-630 - Small Molecule for Retinitis Pigmentosa - Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Small Molecules for CNS Disorders and Ophthalmology - Small Molecules for Retinitis Pigmentosa - Small Molecules for Retinitis Pigmentosa For more information visit http://www.researchandmarkets.com/research/p6vhmx/retinitis
OCAT: 4.27 (-0.15), QLTI: 3.86 (-0.10), ISIS: 52.64 (-1.76), ONCE: 59.83 (-0.49), SHPG: 265.96 (+2.71), CLBS: 1.76 (-0.03)
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
PR Newswire - Tue Jul 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to discuss its second quarter 2015 financial results and report on pipeline and business progress.
ISIS: 52.64 (-1.76)
'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.40 (unch), MMM: 151.37 (+0.26), BIIB: 309.52 (-10.41), ISIS: 52.64 (-1.76), MDSO: 54.21 (-0.03), COP: 52.89 (+0.65), SNDK: 60.51 (-0.57)
Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.40 (unch), MMM: 151.37 (+0.26), AMZN: 527.35 (+1.32), BIIB: 309.52 (-10.41), MDLZ: 43.03 (+0.23), EA: 71.62 (-0.18), SNA: 163.09 (+1.96), NKE: 114.31 (+0.84), MDSO: 54.21 (-0.03), FB: 95.95 (+0.66), FCX: 12.38 (+0.05), COP: 52.89 (+0.65), DIS: 119.36 (+0.90), NFLX: 106.90 (unch), ISIS: 52.64 (-1.76), QLIK: 39.83 (-0.84), KHC: 77.33 (-0.99), GOOGL: 655.37 (-4.29), ULTA: 166.83 (+0.82), CMCSA: 62.37 (-0.04), GIS: 57.50 (-0.05), SNDK: 60.51 (-0.57)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 156.25 (-4.07), BIIB: 309.52 (-10.41), NBIX: 49.88 (-2.04), ISIS: 52.64 (-1.76), SRPT: 31.72 (-0.31), RCPT: 227.90 (+0.74)
ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy
PR Newswire - Mon Jul 27, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today encouraging preliminary results from an investigator-sponsored study in patients with transthyretin amyloid-related cardiomyopathy that was presented yesterday by Dr. Merrill Benson at the 20th World Congress on Heart Disease (WCHD) in Vancouver, Canada.
ISIS: 52.64 (-1.76)
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
PR Newswire - Wed Jul 22, 6:17PM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has published clinical data evaluating ISIS-APO(a)Rx in healthy volunteers with elevated lipoprotein(a) or Lp(a). An accompanying editorial was also published. ISIS-APO(a)Rx is a Generation 2.0+ antisense drug that is part of Isis' lipid franchise, which is being developed and commercialized by Akcea Therapeutics, Isis' wholly owned subsidiary.
ISIS: 52.64 (-1.76)
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 2:20PM CDT
Isis Pharmaceuticals' (ISIS) Huntington's disease candidate, ISIS-HTTRx, moves into a phase I/IIa study; earns a milestone payment of $22 million from Roche.
BIIB: 309.52 (-10.41), ISIS: 52.64 (-1.76), AMAG: 64.41 (-1.82)
Critical Alerts For Isis Pharmaceuticals, NXP Semiconductors, Transocean, Microsoft and Boeing Released By InvestorsObserver
PR Newswire - Wed Jul 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ISIS, NXPI, RIG, MSFT and BA.
RIG: 14.42 (+0.30), ISIS: 52.64 (-1.76), NXPI: 91.71 (+0.67), BA: 143.96 (+2.15), MSFT: 46.51 (+1.17)
Isis Pharmaceuticals begins Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease
M2 - Wed Jul 22, 5:13AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) disclosed on Tuesday the launch of a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease (HD), a rare genetic neurological disease in which patients experience deterioration of both mental abilities and physical control.
ISIS: 52.64 (-1.76)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 99.95 (+0.93), ISIS: 52.64 (-1.76), GILD: 116.67 (+3.60), PFE: 35.68 (+0.33), SGMO: 8.85 (-0.35), BMY: 64.49 (-0.17), NVS: 103.80 (+1.01), XLRN: 28.40 (-0.49)
Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
PR Newswire - Tue Jul 21, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease (HD). ISIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein responsible for HD. HD is a rare genetic neurological disease in which patients experience deterioration of both mental abilities and physical control. Presently, there are no disease-modifying treatments for HD, with current therapies focused only on treating disease symptoms. ISIS-HTTRx has been granted orphan drug designation by the European Medicines Agency for the treatment of patients with HD. Orphan drug designation is granted to products designed to diagnose, prevent or treat life-threatening or very serious conditions that affect not more than five in 10,000 persons in the European Union.
ISIS: 52.64 (-1.76)
Inotek Pharmaceuticals Corporation Appoints Claudine Prowse, Ph.D. as Vice President, Strategy and Investor Relations Officer
Business Wire - Mon Jul 20, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the appointment of Claudine Prowse, Ph.D., as Vice President, Strategy and Investor Relations. Dr. Prowse's responsibilities will include defining corporate strategy to expand business opportunities, corporate communications and investor relations, and interfacing with key external business and investor constituents. She will report directly to David P. Southwell, President and Chief Executive Officer, and serve as a member of the Inotek management team.
ISIS: 52.64 (-1.76), ITEK: 16.99 (-0.11)
'Mad Money' Lightning Round: Buy General Mills, Not B&G Foods
at The Street - Fri Jul 17, 5:00AM CDT
Cramer says TravelCenters of America is a winner, Skyworks Solutions can go higher but he doesn't want to own Apache.
KMI: 34.94 (-0.63), ABB: 19.96 (+0.09), SWKS: 93.99 (-1.69), ISIS: 52.64 (-1.76), BGS: 29.65 (+0.38), VLY: 10.14 (+0.04), APA: 47.03 (+0.56), GIS: 57.50 (-0.05), TA: 15.61 (+0.23)
Jim Cramer's 'Mad Money' Recap: Where Are the Market Winners? Right Here
at The Street - Thu Jul 16, 7:19PM CDT
Cramer says to watch some unfamiliar names in technology plus the bank stocks.
KMI: 34.94 (-0.63), SWKS: 93.99 (-1.69), VLY: 10.14 (+0.04), KEY: 14.94 (+0.13), INTC: 29.04 (+0.08), NFLX: 106.90 (unch), ABB: 19.96 (+0.09), NOW: 77.01 (-1.62), BGS: 29.65 (+0.38), ISIS: 52.64 (-1.76), APA: 47.03 (+0.56), DPZ: 112.60 (+0.83), DATA: 103.38 (-23.69), MSFT: 46.51 (+1.17), GIS: 57.50 (-0.05), TA: 15.61 (+0.23)
Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 3:30PM CDT
Isis Pharmaceuticals (ISIS) earned a milestone payment of $2.15 million from Biogen for the advancement of ISIS-SMNRx in children with spinal muscular atrophy.
BIIB: 309.52 (-10.41), ISIS: 52.64 (-1.76), EBIO: 2.79 (+0.03), AMAG: 64.41 (-1.82)
Isis Pharmaceuticals Rises 4.67% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 14, 4:27PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $53.50 to a high of $56.64. Yesterday, the shares gained 4.7%, which took the trading range above the 3-day high of $54.87 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 52.64 (-1.76)
8 Companies With Accidentally Disastrous Names
at The Street - Tue Jul 14, 8:49AM CDT
From Isis Pharmaceuticals to Kony Inc. to Grexit, these companies have had to deal with grim news events casting a cloud over their names.
ISIS: 52.64 (-1.76)
Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy
PR Newswire - Tue Jul 14, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). To date, Isis has generated more than $120 million in payments from Biogen related to the development of ISIS-SMNRx.
ISIS: 52.64 (-1.76)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - 19 mins ago
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.35 (unch), KNMD: (), VTAE: 9.81 (-0.09), LLY: 85.01 (-0.67), OMER: 16.10 (-0.26), JNJ: 99.95 (+0.93), ISIS: 52.64 (-1.76), OPK: 16.67 (-0.17), GILD: 116.67 (+3.60), AZN: 32.83 (+0.02), MRK: 58.73 (+1.21), CCXI: 8.52 (-0.10), VBLT: 6.13 (-0.02), NVS: 103.80 (+1.01)
Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles
M2 - Tue Jul 28, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vhmx/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - BioDiem Ltd - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - R-Tech Ueno, Ltd. - ReNeuron Group Plc - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AMRS-001 - Antibodies to Antagonize IL-6 for Retinitis - BDM-E - BNP-RP - CB-11 - ECL-1 - emixustat hydrochloride - FIB-111 - Gene Therapy for Glaucoma and Retinitis Pigmentosa - Gene Therapy for Ocular Diseases - Gene Therapy for Ophthalmology - Gene Therapy for Retinitis Pigmentosa - Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - GS-020 - GT-038 - ISISRHO-2.5Rx - KIRA-6 - NT-501 - OCU-100 - PRO-015 - proinsulin human SR - QLT-091001 - Recombinant Human Nerve Growth Factor - ReN-003 - Retinal Progenitor Cells for Ophthalmological Disorders - RGX-321 - RST-001 - SAR-421869 - SHP-630 - Small Molecule for Retinitis Pigmentosa - Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Small Molecules for CNS Disorders and Ophthalmology - Small Molecules for Retinitis Pigmentosa - Small Molecules for Retinitis Pigmentosa For more information visit http://www.researchandmarkets.com/research/p6vhmx/retinitis
OCAT: 4.27 (-0.15), QLTI: 3.86 (-0.10), ISIS: 52.64 (-1.76), ONCE: 59.83 (-0.49), SHPG: 265.96 (+2.71), CLBS: 1.76 (-0.03)
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
PR Newswire - Tue Jul 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to discuss its second quarter 2015 financial results and report on pipeline and business progress.
ISIS: 52.64 (-1.76)
'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.40 (unch), MMM: 151.37 (+0.26), BIIB: 309.52 (-10.41), ISIS: 52.64 (-1.76), MDSO: 54.21 (-0.03), COP: 52.89 (+0.65), SNDK: 60.51 (-0.57)
Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.40 (unch), MMM: 151.37 (+0.26), AMZN: 527.35 (+1.32), BIIB: 309.52 (-10.41), MDLZ: 43.03 (+0.23), EA: 71.62 (-0.18), SNA: 163.09 (+1.96), NKE: 114.31 (+0.84), MDSO: 54.21 (-0.03), FB: 95.95 (+0.66), FCX: 12.38 (+0.05), COP: 52.89 (+0.65), DIS: 119.36 (+0.90), NFLX: 106.90 (unch), ISIS: 52.64 (-1.76), QLIK: 39.83 (-0.84), KHC: 77.33 (-0.99), GOOGL: 655.37 (-4.29), ULTA: 166.83 (+0.82), CMCSA: 62.37 (-0.04), GIS: 57.50 (-0.05), SNDK: 60.51 (-0.57)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 156.25 (-4.07), BIIB: 309.52 (-10.41), NBIX: 49.88 (-2.04), ISIS: 52.64 (-1.76), SRPT: 31.72 (-0.31), RCPT: 227.90 (+0.74)
ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy
PR Newswire - Mon Jul 27, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today encouraging preliminary results from an investigator-sponsored study in patients with transthyretin amyloid-related cardiomyopathy that was presented yesterday by Dr. Merrill Benson at the 20th World Congress on Heart Disease (WCHD) in Vancouver, Canada.
ISIS: 52.64 (-1.76)
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
PR Newswire - Wed Jul 22, 6:17PM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has published clinical data evaluating ISIS-APO(a)Rx in healthy volunteers with elevated lipoprotein(a) or Lp(a). An accompanying editorial was also published. ISIS-APO(a)Rx is a Generation 2.0+ antisense drug that is part of Isis' lipid franchise, which is being developed and commercialized by Akcea Therapeutics, Isis' wholly owned subsidiary.
ISIS: 52.64 (-1.76)
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 2:20PM CDT
Isis Pharmaceuticals' (ISIS) Huntington's disease candidate, ISIS-HTTRx, moves into a phase I/IIa study; earns a milestone payment of $22 million from Roche.
BIIB: 309.52 (-10.41), ISIS: 52.64 (-1.76), AMAG: 64.41 (-1.82)
Critical Alerts For Isis Pharmaceuticals, NXP Semiconductors, Transocean, Microsoft and Boeing Released By InvestorsObserver
PR Newswire - Wed Jul 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ISIS, NXPI, RIG, MSFT and BA.
RIG: 14.42 (+0.30), ISIS: 52.64 (-1.76), NXPI: 91.71 (+0.67), BA: 143.96 (+2.15), MSFT: 46.51 (+1.17)
Isis Pharmaceuticals begins Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease
M2 - Wed Jul 22, 5:13AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) disclosed on Tuesday the launch of a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease (HD), a rare genetic neurological disease in which patients experience deterioration of both mental abilities and physical control.
ISIS: 52.64 (-1.76)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 99.95 (+0.93), ISIS: 52.64 (-1.76), GILD: 116.67 (+3.60), PFE: 35.68 (+0.33), SGMO: 8.85 (-0.35), BMY: 64.49 (-0.17), NVS: 103.80 (+1.01), XLRN: 28.40 (-0.49)
Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
PR Newswire - Tue Jul 21, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease (HD). ISIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein responsible for HD. HD is a rare genetic neurological disease in which patients experience deterioration of both mental abilities and physical control. Presently, there are no disease-modifying treatments for HD, with current therapies focused only on treating disease symptoms. ISIS-HTTRx has been granted orphan drug designation by the European Medicines Agency for the treatment of patients with HD. Orphan drug designation is granted to products designed to diagnose, prevent or treat life-threatening or very serious conditions that affect not more than five in 10,000 persons in the European Union.
ISIS: 52.64 (-1.76)
Inotek Pharmaceuticals Corporation Appoints Claudine Prowse, Ph.D. as Vice President, Strategy and Investor Relations Officer
Business Wire - Mon Jul 20, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the appointment of Claudine Prowse, Ph.D., as Vice President, Strategy and Investor Relations. Dr. Prowse's responsibilities will include defining corporate strategy to expand business opportunities, corporate communications and investor relations, and interfacing with key external business and investor constituents. She will report directly to David P. Southwell, President and Chief Executive Officer, and serve as a member of the Inotek management team.
ISIS: 52.64 (-1.76), ITEK: 16.99 (-0.11)
'Mad Money' Lightning Round: Buy General Mills, Not B&G Foods
at The Street - Fri Jul 17, 5:00AM CDT
Cramer says TravelCenters of America is a winner, Skyworks Solutions can go higher but he doesn't want to own Apache.
KMI: 34.94 (-0.63), ABB: 19.96 (+0.09), SWKS: 93.99 (-1.69), ISIS: 52.64 (-1.76), BGS: 29.65 (+0.38), VLY: 10.14 (+0.04), APA: 47.03 (+0.56), GIS: 57.50 (-0.05), TA: 15.61 (+0.23)
Jim Cramer's 'Mad Money' Recap: Where Are the Market Winners? Right Here
at The Street - Thu Jul 16, 7:19PM CDT
Cramer says to watch some unfamiliar names in technology plus the bank stocks.
KMI: 34.94 (-0.63), SWKS: 93.99 (-1.69), VLY: 10.14 (+0.04), KEY: 14.94 (+0.13), INTC: 29.04 (+0.08), NFLX: 106.90 (unch), ABB: 19.96 (+0.09), NOW: 77.01 (-1.62), BGS: 29.65 (+0.38), ISIS: 52.64 (-1.76), APA: 47.03 (+0.56), DPZ: 112.60 (+0.83), DATA: 103.38 (-23.69), MSFT: 46.51 (+1.17), GIS: 57.50 (-0.05), TA: 15.61 (+0.23)
Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 3:30PM CDT
Isis Pharmaceuticals (ISIS) earned a milestone payment of $2.15 million from Biogen for the advancement of ISIS-SMNRx in children with spinal muscular atrophy.
BIIB: 309.52 (-10.41), ISIS: 52.64 (-1.76), EBIO: 2.79 (+0.03), AMAG: 64.41 (-1.82)
Isis Pharmaceuticals Rises 4.67% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 14, 4:27PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $53.50 to a high of $56.64. Yesterday, the shares gained 4.7%, which took the trading range above the 3-day high of $54.87 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 52.64 (-1.76)
8 Companies With Accidentally Disastrous Names
at The Street - Tue Jul 14, 8:49AM CDT
From Isis Pharmaceuticals to Kony Inc. to Grexit, these companies have had to deal with grim news events casting a cloud over their names.
ISIS: 52.64 (-1.76)
Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy
PR Newswire - Tue Jul 14, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). To date, Isis has generated more than $120 million in payments from Biogen related to the development of ISIS-SMNRx.
ISIS: 52.64 (-1.76)
